Epiretinal Implant Electrode Array Durability 2026
Epiretinal Implant Electrode Array Durability
Durability is the critical limiting factor for epiretinal implant adoption, spanning electrode material stability, substrate integrity, mechanical fixation, and tissue response. This landscape synthesizes 60+ retrieved patent and literature records from 1998 to 2026.
Four Interacting Engineering Challenges Define Epiretinal Implant Durability
Epiretinal implants are positioned on the inner retinal surface, fixed by a retinal tack, and deliver charge-balanced biphasic pulses through platinum, iridium oxide, or novel-material electrode arrays to surviving retinal ganglion cells. The central clinical reference in this dataset is the Argus II (Second Sight Medical Products / Cortigent), with secondary clinical systems including the IMIE 256 and NR600.
Electrode material electrochemical stability is the first durability pillar. Sputtered iridium oxide films (SIROF) and electrodeposited iridium oxide (EIROF) offer high charge injection capacity compared to bare platinum, enabling safe long-duration charge delivery without Faradaic corrosion products. Preclinical feline implantation data showed platinum electrodes maintaining stable impedance over 96–143 days of chronic use.
Flexible substrate integrity is the second pillar. Polyimide has been the dominant substrate due to MEMS-processability, biocompatibility, and flexibility. Parylene-C serves as encapsulation coating, PDMS enables 3D pillar geometries, and liquid crystal polymer (LCP) monolithic substrates represent a key advance for hermetic sealing and scleral anchoring. A 2018 study of eleven rabbit LCP implantations reported 90.9% well-tolerated at three months.
Mechanical interface stability and biological host response constitute the third and fourth pillars. Clinical OCT evidence from Argus II users demonstrates that electrode-retina gap distance directly correlates with stimulation threshold and is subject to post-operative change through epiretinal fibrosis. In this dataset, no patent explicitly claims anti-fibrotic surface coatings or active gap-monitoring systems — representing a notable white space for IP development.
Innovation Phasing and Technology Cluster Distribution in Retrieved Records
Retrieved records cluster into three innovation phases — Foundational (1998–2006), Development and Clinical Validation (2007–2018), and Next-Generation and Emerging (2019–2026) — with the most recent active filings concentrated in novel electrode geometries and graphene materials.
Patent Records by Technology Cluster (Dataset Snapshot)
In this dataset, electrode material stability and flexible substrate engineering together account for the largest share of retrieved patent and literature records, while novel geometry and emerging material clusters show the strongest recent growth from 2019 onward.
↗ Click bars to exploreFiling Activity by Innovation Phase, 1998–2026 (Retrieved Records)
In this dataset, the Development and Clinical Validation phase (2007–2018) produced the greatest volume of retrieved records, while the Next-Generation phase (2019–2026) shows accelerating activity with the most recent filing dated 2026.
↗ Click bars to exploreClinical Targets and Cross-Domain Transfer in Epiretinal Implant Durability
Durability technologies developed for epiretinal implants serve multiple clinical and research contexts, from retinitis pigmentosa as the primary target, to age-related macular degeneration and neural prosthetics, where material degradation benchmarks transfer directly from cortical implant explant studies.
Retinitis Pigmentosa — Primary Target
The Argus II, IMIE 256, and OPTO-EPIRET are each explicitly indicated for RP patients with no light perception or bare light perception. The 256-channel IMIE 256 trial enrolled five RP subjects showing significant improvement in grating acuity, direction of motion, and orientation/mobility tasks. Electrode array movement was cited as one of two serious adverse events in the IMIE 256 trial, directly implicating mechanical durability as a clinical risk factor.
Primary Clinical TargetAge-Related Macular Degeneration
The NR600 needle-shaped electrode array device is explicitly intended for both RP and AMD populations. The Pixium Vision PRIMA photovoltaic system durability study tested 175 implants for up to 33 months using real-time (37°C BSS), accelerated Arrhenius (up to 87°C), and overstimulation (6× pulsed laser) protocols — the most extensive in vitro aging dataset in this collection. This methodology is positioned as an emerging benchmark for preclinical lifespan estimation across retinal prosthesis platforms.
Emerging Clinical TargetNeural Prosthetics BCI Cross-Domain
Explant data from cortical BCI Utah Electrode Arrays provides directly transferable material degradation benchmarks for epiretinal electrode durability. Six arrays explanted from two human participants at implant durations of 182 days and 980 days provide the only human explant characterization dataset at ~980 days in the retrieved records. Material integrity and tissue encapsulation evidence for platinum and IrOx electrodes at these durations establishes a key durability baseline applicable to epiretinal contexts.
Cross-Domain TransferWireless Photovoltaic Epiretinal Systems
Foldable POLYRETINA (2018) and the switched microlens array (SLSMA, 2024 Glaive Medical Optics) represent architectures that reduce or eliminate chronic metal electrode contact with retinal tissue. Accelerated aging of POLYRETINA showed an estimated lifetime of ≥2 years, while SLSMA proposes a less invasive optical approach to avoid electrode material degradation. The wide-field photovoltaic prosthesis design addresses both stimulation coverage and long-term material stability simultaneously.
Emerging ArchitectureLeading Patent Assignees in Epiretinal Implant Durability — Dataset Snapshot
In this dataset, Second Sight Medical Products (now Cortigent) and Pixium Vision SA together account for the majority of retrieved patent records, with at least 10 and 9 distinct patent families respectively. However, the most recent active filings in retrieved records increasingly originate from academic institutions including IIT Kharagpur, Gachon University, and Peking University.
Top Assignees by Patent Filings in Retrieved Records (Dataset Snapshot)
↗ Click bars to exploreSecond Sight Medical Products
Second Sight Medical Products is the most prolific assignee in this dataset, with at least 10 distinct patent families across US, AU, and EP jurisdictions filed from 2002 onward, covering dual-array architecture, array fixation methods, and impedance-based fitting systems. Key patents include the Argus II retinal electrode array configuration for minimal retinal damage and a separate central and peripheral electrode array design prosecuted across multiple jurisdictions. The company is now operating as Cortigent, with active US patents covering the core tack-based epiretinal fixation approach.
United StatesPixium Vision SA
Pixium Vision SA holds at least 9 patent documents in this dataset, covering transretinal stimulation architectures across EP, ES, AU, US, and NZ jurisdictions, primarily addressing electrode configuration for minimal tissue damage. A key 2002 US patent established the stimulating and ground return electrode configuration, and the 2020 PRIMA reliability study tested 175 implants for up to 33 months using real-time and accelerated Arrhenius aging protocols. Pixium Vision’s filings represent one of the most geographically diverse prosecution strategies in the epiretinal implant patent landscape within retrieved records.
France — EP / US / AUFive Emerging Technology Vectors in Epiretinal Implant Durability (2019–2026)
The most recent filings and publications in this dataset signal five distinct directions that are reshaping how durability is engineered into next-generation epiretinal systems, from novel carbon materials to accelerated aging standardization.
Graphene Honeycomb Electrodes: Structural and Thermal Durability
The IIT Kharagpur honeycomb graphene MEA patent (IN, 2026) is the most recent filing in this dataset. Graphene offers superior charge injection, biocompatibility, mechanical flexibility, and thermal conductivity compared to IrOx — directly addressing thermal safety and long-term structural degradation. The hexagonal honeycomb pattern is claimed to improve electric field control and heat dissipation simultaneously under chronic stimulation conditions.
Accelerated Aging Protocols as Durability Standardization
The Pixium PRIMA study tested 175 implants for up to 33 months using real-time (37°C BSS), accelerated Arrhenius (up to 87°C), and overstimulation (6× pulsed laser) protocols — the most methodologically rigorous durability dataset in this collection. This multi-temperature, multi-stressor approach is positioned to become the benchmark for preclinical lifespan estimation. Entrants without equivalent aging data will face regulatory and competitive barriers in this field.
Sputtered Iridium Oxide (SIROF) vs. Graphene Electrode Materials for Epiretinal Arrays
Click any row to explore further.
| Dimension | SIROF / IrOx | Graphene (Honeycomb MEA) |
|---|---|---|
| Clinical Stage | Clinical — used in Argus II, Alpha AMS (Retina Implant AG) | Preclinical — IIT Kharagpur IN patent filed 2026 |
| Charge Injection Capacity | High CIC and CSC vs. bare platinum; safe long-duration delivery documented | Claimed superior charge injection in honeycomb geometry patent |
| Impedance Stability | ~10% impedance variation across wide process window (Retina Implant AG, 2020) | Not yet characterized in chronic in vivo conditions |
| Thermal Safety”> | Not explicitly addressed in retrieved SIROF records | Honeycomb pattern claimed to improve heat dissipation under chronic stimulation |
| Mechanical Flexibility | Deposited on polyimide or parylene substrates; substrate provides flexibility | Graphene inherently flexible; claimed superior mechanical flexibility vs. IrOx |
| Minimum Electrode Size | 10–30 µm diameter evaluated for high visual acuity subretinal stimulation (2021) | Cellular-scale pixel targeting stated; specific dimensions not reported in dataset |
| Long-Term Degradation Evidence | Utah Array explants at 980 days show material degradation correlated with performance decline | No long-term in vivo degradation data in retrieved records |
| IP Status in Dataset | Core claims from Second Sight, Cortigent, Retina Implant AG — active through 2020s | Single active IN patent (IIT Kharagpur, 2026); open IP landscape for novel claims |
Frequently Asked Questions: Epiretinal Implant Electrode Array Durability
Based on retrieved records, the four interacting challenges are: (1) electrode material electrochemical stability under chronic stimulation, (2) flexible substrate mechanical integrity and encapsulation against saline ingress, (3) mechanical interface stability between the array and retinal tissue, and (4) the biological response of the retina to the implant over years of contact.
Clinical-stage epiretinal devices in this dataset primarily use sputtered iridium oxide films (SIROF) and electrodeposited iridium oxide (EIROF) as electrode coatings, along with bare platinum. These materials offer high charge injection capacity and charge storage capacity compared to bare platinum. Emerging materials including graphene and fractal geometries appear in the most recent filings (2019–2026).
Epiretinal fibrosis is a biological response in which a hyperreflective fibrous band forms between the electrode array and the retinal surface. A 2021 case report of an Argus II patient documented fibrosis causing loss of electrode function and threshold elevation over 12 months. A five-patient OCT study confirmed that increased gap distance between the electrode array and retina directly correlates with elevated stimulation thresholds and reduced visual function.
The most recent filing in this dataset is the Indian Institute of Technology Kharagpur honeycomb graphene microelectrode array patent (IN, 2026). It targets structural integrity, heat dissipation, and long-term performance under chronic stimulation through a hexagonal honeycomb graphene pattern designed to improve electric field control and heat dissipation simultaneously.
The Pixium Vision PRIMA study tested 175 implants for up to 33 months using three protocols: real-time testing at 37°C in balanced salt solution (BSS), accelerated Arrhenius testing at temperatures up to 87°C, and overstimulation testing at 6× the normal pulsed laser intensity. This is described as the most methodologically rigorous durability dataset in the retrieved collection.
Among retrieved results, dominant substrate materials are polyimide (PI), parylene-C, polydimethylsiloxane (PDMS), and liquid crystal polymer (LCP). Polyimide is dominant due to MEMS-processability and biocompatibility. Parylene-C is used as an encapsulation coating. LCP monolithic substrates integrate packaging and array in one body, representing an advance for hermetic sealing. An eleven-rabbit LCP implantation study reported 90.9% well-tolerated at three months.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.